Literature DB >> 3124857

Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes.

J O Miners1, K J Lillywhite, A P Matthews, M E Jones, D J Birkett.   

Abstract

The glucuronidation kinetics of 4-methylumbelliferone (4MU) and 1-naphthol (1NP) have been investigated in human liver microsomes to determine the validity of using these compounds as probes for specific UDP-glucuronosyltransferase (GT) activities in human liver. 4MU glucuronidation followed Michaelis-Menten kinetics, whereas 1NP glucuronidation kinetics were biphasic. Cross inhibition studies were performed with 4MU and 1NP to determine the relationship between 4MU glucuronidation and the two phases of 1NP glucuronidation. 4MU glucuronidation was competitively inhibited by 1NP but 4MU inhibited only the high affinity component of 1NP glucuronidation. There was good agreement between the apparent Km values for 4MU and the high affinity component of 1NP glucuronidation and their respective apparent K1 values determined in the cross inhibition studies. These data suggest that the same form(s) of human liver GT is involved in 4MU glucuronidation and the high affinity component of 1NP glucuronidation. A number of compounds known to be specific substrates for purified rat liver GTs were screened for inhibitory effects on 4MU glucuronidation in human liver microsomes. 4-Nitrophenol, 2-aminophenol and androsterone inhibited 4MU glucuronidation whereas bilirubin, chloramphenicol, digitoxigenin monodigitoxoside, morphine, oestrone and testosterone had no effect. 4-Nitrophenol and 2-aminophenol were competitive inhibitors of 4MU glucuronidation but the inhibition of 4MU glucuronidation by androsterone followed atypical kinetics. Overall, the substrate specificity of the human liver 4MU/high affinity 1NP-GT activity appears to be broadly similar to that of the 3-methylcholanthrene inducible rat hepatic microsomal GT.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3124857     DOI: 10.1016/0006-2952(88)90140-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Cloning and stable expression of a new member of the human liver phenol/bilirubin: UDP-glucuronosyltransferase cDNA family.

Authors:  R Wooster; L Sutherland; T Ebner; D Clarke; O Da Cruz e Silva; B Burchell
Journal:  Biochem J       Date:  1991-09-01       Impact factor: 3.857

2.  Immunochemical analysis of uridine diphosphate-glucuronosyltransferase in four patients with the Crigler-Najjar syndrome type I.

Authors:  H H van Es; B G Goldhoorn; M Paul-Abrahamse; R P Elferink; P L Jansen
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

3.  Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells.

Authors:  D Harding; S Fournel-Gigleux; M R Jackson; B Burchell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

4.  Expression of a high-affinity form of UDP-glucuronosyltransferase in human foetal liver cells in culture on exposure to mercuric chloride.

Authors:  T M Tan; K P Wong; K H Sit
Journal:  Biochem J       Date:  1991-08-15       Impact factor: 3.857

5.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.

Authors:  Sam Boase; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

6.  Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation.

Authors:  Verawan Uchaipichat; Leanne K Winner; Peter I Mackenzie; David J Elliot; J Andrew Williams; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

Review 7.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

Review 8.  Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).

Authors:  Kathleen M Knights; Andrew Rowland; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

9.  Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.

Authors:  Andrew Rowland; Warit Ruanglertboon; Madelé van Dyk; Dhilushi Wijayakumara; Linda S Wood; Robyn Meech; Peter I Mackenzie; A David Rodrigues; Jean-Claude Marshall; Michael J Sorich
Journal:  Br J Clin Pharmacol       Date:  2018-11-16       Impact factor: 4.335

10.  Delta 2-valproate biotransformation using human liver microsomal fractions.

Authors:  G Fabre; C Briot; E Marti; J P Montseny; M Bourrié; D Massé; Y Berger; J P Cano
Journal:  Pharm Weekbl Sci       Date:  1992-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.